Halozyme Therapeutics HALO
$91.35 −$1.69 (-1.82%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $91.35 0.00%
Open$93.64
Prev close$93.04
Day range$90.79 – $93.64
Volume1.50M
Market cap$10.41B
P/E (TTM)22.8
Dividend yield–
Earnings
Average move on report day±7.9%last 16 reports
Closed higher12 of 1675% of the time
Best reaction+20.2%
Worst reaction-15.7%
Stock move on the day after each report
| Quarter | Report date | Timing | Implied move | Actual move | Versus implied |
|---|---|---|---|---|---|
| 2026/Q3 | 5 Nov 2026 | After Market | ±8.5% | -15.72% | Bigger than priced |
| 2026/Q2 | 6 Aug 2026 | After Market | ±5.9% | +20.24% | Bigger than priced |
| 2026/Q1 | 11 May 2026 | After Market | ±4.6% | +6.81% | Bigger than priced |
| 2025/Q4 | 17 Feb 2026 | After Market | ±3.4% | -9.01% | Bigger than priced |
| 2025/Q3 | 3 Nov 2025 | After Market | ±8.5% | +2.79% | Within range |
| 2025/Q2 | 5 Aug 2025 | After Market | ±10.4% | +2.48% | Within range |
| 2025/Q1 | 6 May 2025 | After Market | ±9.5% | +18.12% | Bigger than priced |
| 2024/Q4 | 18 Feb 2025 | After Market | ±7.7% | -0.22% | Within range |
| 2024/Q3 | 31 Oct 2024 | After Market | ±10.1% | +13.01% | Bigger than priced |
| 2024/Q2 | 6 Aug 2024 | After Market | ±9.6% | +4.20% | Within range |
| 2024/Q1 | 7 May 2024 | After Market | ±10.6% | +1.94% | Within range |
| 2023/Q4 | 20 Feb 2024 | After Market | ±12.4% | +6.56% | Within range |
| 2023/Q3 | 6 Nov 2023 | After Market | ±9.7% | +10.04% | Bigger than priced |
| 2023/Q2 | 8 Aug 2023 | After Market | ±9.1% | -1.57% | Within range |
| 2023/Q1 | 9 May 2023 | After Market | ±12.0% | +12.79% | Bigger than priced |
| 2022/Q4 | 21 Feb 2023 | After Market | ±11.5% | +0.85% | Within range |
"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$492.97M+39.2% YoY
Operating profit$294.97M+35.4% YoY
Net profit$247.05M+41.0% YoY
Diluted EPS$2.01+40.6% YoY
Free cash flow$255.22M+45.4% YoY
Operating cash flow$258.27M
Revenue, last 8 quarters
Net profit, last 8 quarters
Profitability & balance sheet
Gross margin82.3%
Operating margin55.9%
Net margin26.9%
Return on equity216.4%
Return on assets17.0%
Return on invested capital19.3%
Current ratio3.88
Liabilities / assets101.6%
Cash & investments$1.07B
Total debt$3.25B
Net cash (debt)-$2.18B
Free cash flow / sales33.2%
No comments yet — be the first to weigh in on HALO.
Sign in to join the discussion.